A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
A phase 2 trial of Enfortumab vedotin and Pembrolizumab in advanced solid tumours, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
Overview
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) is a phase 2 interventional study registered as NCT04225117 by Astellas Pharma Global Development, Inc., with 329 participants enrolled, started 2020-03-10 and due to reach its primary completion in 2025-02-25. Interventions recorded: enfortumab vedotin and pembrolizumab. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Pembrolizumab and the tag pipeline.
- TrialA Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Shares Astellas, Enfortumab vedotin, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen) and the tag pipeline.
- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Pembrolizumab and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.